Gemcitabine SEDICO vials

Gemcitabine is a chemotherapy drug widely used to treat several solid tumors, including pancreatic, lung, breast, bladder, and ovarian cancers. It works by interfering with DNA synthesis, preventing cancer cells from dividing and multiplying. --- 🔬 What Gemcitabine Is - Chemical identity: Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a nucleoside analog of cytidine. - Drug class: It belongs to the antimetabolite group of chemotherapy agents. - Trade name: Commonly marketed as Gemzar. - Formulation: Available as a lyophilized powder for intravenous infusion. --- ⚙️ Mechanism of Action - Gemcitabine is incorporated into DNA during replication. - It inhibits DNA polymerase and blocks the enzyme ribonucleotide reductase, reducing the pool of nucleotides needed for DNA synthesis. - This leads to cell cycle arrest in the S-phase and ultimately triggers apoptosis (cell death). - Its cytotoxic effect depends on both drug concentration and duration of exposure. --- 💊 Clinical Uses Gemcitabine is indicated for multiple cancers, often alone or in combination with other agents: - Pancreatic cancer: Standard first-line treatment for locally advanced or metastatic disease. - Non-small cell lung cancer (NSCLC): Used with cisplatin. - Breast cancer: Often combined with paclitaxel. - Bladder cancer: Combined with cisplatin for advanced cases. - Ovarian cancer: Sometimes used in recurrent disease. --- 📈 Pharmacokinetics - Administration: Intravenous infusion only. - Protein binding: Less than 10%. - Half-life: - Short infusions: 32–94 minutes. - Long infusions: 245–638 minutes. - Metabolism: Primarily metabolized in the liver by cytidine deaminase. - Excretion: Mainly via urine. --- ⚠️ Side Effects and Risks - Common side effects: Fatigue, nausea, vomiting, fever, rash, and flu-like symptoms. - Hematologic toxicity: Neutropenia, anemia, thrombocytopenia. - Hepatic toxicity: Elevated liver enzymes.